Recent Finacing
Recent Raise
Omthera Pharmaceuticals develops dyslipidemia therapies, advancing Epanova, an EPA/DHA omega‑3 formulation targeting elevated triglycerides, through late‑stage clinical development and global commercialization rights.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors